LDRA
11.5.2021 14:02:16 CEST | Business Wire | Press release
The Embedded Safety & Security Summit (ESSS) today announced its first set of speakers for the inaugural virtual event, scheduled for June 17, 2021. Based on LDRA’s long-running annual conference, ESSS brings together embedded technology enthusiasts, industry thought leaders and regulators worldwide to share emerging trends, best practices, technical deep dive, and practical examples on empowering the development of safe and secure embedded systems.
In addition to Ian Hennell, Operations Director of LDRA, confirmed speakers and their presentations include:
Technical Panel : Next-gen Technologies: Safety and Security Implications
Dr Nigel Tracey, Vice President – RTA Solutions, ETAS, Germany
Suresh Kumar R, CTO CCS India & Digital Incubators, GE-Healthcare, India
Bill. St. Clair, Director – US Operations, LDRA, USA
Shinto Joseph, Director – South East Asia Operations, LDRA, India
Industrial Cybersecurity System (ICS) defenses what is next?
Felipe Sabino Costa, LATAM Industrial Cybersecurity (IACS) Expert, Brazil
MISRA C in the ISO 26262 Context
Andrew Banks, Chairman of the MISRA C Working Group, Technical Specialist, LDRA, UK
UNECE WP.29 Regulations for Automotive Security – A View from India
Khushwant Pawar, Head, Cybersecurity Solutions – Mobility, ETAS, India
Balancing the Load of a Safety Critical Multi Core System
Mohamed Zuhair, Electronics Engineer, TASKING, India
Challenges in Testing & Certification of AI-ML based systems in Aerospace
Shashi Kumar P, Principal Engineer – Certification, Honeywell Aerospace, India
Koilpillai George, Chief Engineers – Software, Honeywell Aerospace, India
Do All Your Build Tools Need To Be Qualified?
Chris Tapp, Chairman of the MISRA C++ Working Group, Technical Specialist, LDRA, UK
Hardware Enablers for Security in Industrial IoT
Mini TT, Principal Engineer, ABB, India
FACE Standard Verification and Validation for Safety Environments
Ehsan Salehi, Field Application Manager & FACE™ VA, LDRA, USA
System Safety Enhancement using Fault Tolerant Design
Manju Maheve, System Safety Engineer, Collins Aerospace, India
Priya Peter, System Safety and Reliability Engineer, Collins Aerospace, India
Verification Activities to be Considered for Achieving IEC 62304 Compliance
Anil Kumar N.G, Sr. Technical Manager, LDRA, India
“The deep-dive technical sessions from industry experts across the aerospace & defence, automotive, industrial, and medical domain offer an ideal mix of insights into the growing significance of implementing safe and secure practices and technologies in embedded systems,” Hennell said. “While we’ll miss being in-person this year, we expect even more within the embedded community will benefit from these valuable virtual sessions and the networking opportunities that everyone has grown to expect at ESSS.”
The virtual conference platform will offer industry-focused tracks and allow myriad networking opportunities for attendees and speakers with chat room features and live Q&As. For more information and to register for free, please visit https://www.embedded-safety-security.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005073/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom